Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Influenza vaccine

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    463 result(s) found for: Influenza vaccine. Displaying page 1 of 24.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2014-000785-21 Sponsor Protocol Number: GQM11 Start Date*: 2014-07-24
    Sponsor Name:Sanofi Pasteur
    Full Title: Immunogenicity and Lot-to-Lot Consistency Study of a Quadrivalent Influenza Vaccine in Adult and Elderly Subjects
    Medical condition: Prevention of influenza infection in adults from 18 years of age
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004862 10022001 Influenza (epidemic) LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2012-005243-25 Sponsor Protocol Number: GID37 Start Date*: 2013-04-16
    Sponsor Name:Sanofi Pasteur
    Full Title: Immunogenicity and Safety of the Trivalent Influenza Vaccine (Split-Virion, Inactivated), Northern Hemisphere 2013-2014 Formulation (Intradermal Route)
    Medical condition: Prophylaxis of influenza (2013-2014 Northern Hemisphere Season)
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004862 10022001 Influenza (epidemic) LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2017-003467-34 Sponsor Protocol Number: FinFLU_HCPimmu_2017THL Start Date*: 2017-10-17
    Sponsor Name:Terveyden ja hyvinvoinnin laitos (THL)
    Full Title: Immune responses to influenza vaccinations and viruses among health care personnel
    Medical condition:
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000022896 10059430 Influenza immunization LLT
    20.0 100000015765 10022001 Influenza (epidemic) LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FI (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-003953-43 Sponsor Protocol Number: VAC31518COV3005 Start Date*: 2021-11-29
    Sponsor Name:Janssen Vaccines & Prevention B.V.
    Full Title: A Randomized, Double-blind, Phase 3 Study to Evaluate Safety, Reactogenicity, and Immunogenicity of Co-administration of Ad26.COV2.S and Influenza Vaccines in Healthy Adults 18 Years of Age and Older
    Medical condition: Healthy Volunteers (Prevention of COVID-19 and influenza)
    Disease: Version SOC Term Classification Code Term Level
    23.1 100000004865 10084465 COVID-19 vaccination LLT
    21.1 100000004865 10059430 Influenza immunization LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2018-001857-29 Sponsor Protocol Number: V130_14 Start Date*: 2019-03-13
    Sponsor Name:Seqirus UK Limited
    Full Title: A Phase III, Randomized, Observer-blind, Multicenter Study to Evaluate the Efficacy, Immunogenicity and Safety of Seqirus' Cell-Based Quadrivalent Subunit Influenza Virus Vaccine (QIVc) Compared to...
    Medical condition: Prophylaxis of influenza virus infection
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10022000 Influenza PT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: BG (Completed) EE (Completed) CZ (Completed) LV (Completed) PL (Completed) Outside EU/EEA RO (Ongoing)
    Trial results: View results
    EudraCT Number: 2014-000629-19 Sponsor Protocol Number: GID47 Start Date*: 2014-08-21
    Sponsor Name:Sanofi Pasteur
    Full Title: Safety assessment of the Trivalent Influenza Vaccine (Split-Virion, Inactivated), Northern Hemisphere 2014-2015 Formulation (Intradermal Route)
    Medical condition: Prophylaxis of influenza (2014-2015 Northern Hemisphere Season)
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004862 10022001 Influenza (epidemic) LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-000165-38 Sponsor Protocol Number: V87P1E1 Start Date*: 2007-06-22
    Sponsor Name:NOVARTIS VACCINES AND DIAGNOSTICS S.R.L.
    Full Title: A Phase II, Open-label, Multi-Center Study to Evaluate Safety and Immunogenicity of a Booster Dose of FLUAD-H5N1 (Surface Antigen Adjuvanted with MF59C.1) Influenza Vaccine in Non-elderly Adult an...
    Medical condition: Active immunoprofilaxis against potential pandemic influenza strain.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10059429 Influenza immunisation LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2006-004063-66 Sponsor Protocol Number: V87P2 Start Date*: 2006-10-30
    Sponsor Name:CHIRON
    Full Title: A Phase II, Randomized, Controlled, Observer-blind, Single-Center Study to Evaluate Safety and Immunogenicity of Two Doses, Administered Three Weeks Apart, and a Six Month Booster Dose of Two FLUAD...
    Medical condition: Active influenza profilaxis pandemic strain
    Disease: Version SOC Term Classification Code Term Level
    8.1 10022000 Influenza LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2018-001894-26 Sponsor Protocol Number: CP-PRO-QVLP-014 Start Date*: 2018-10-18
    Sponsor Name:Medicago R&D Inc.
    Full Title: A Randomized, Observer-blind, Active Comparator-controlled, Multicenter, Phase 3 Study to Assess the Efficacy, Safety, and Immunogenicity of a Plant-derived Quadrivalent VLP Influenza Vaccine in Ad...
    Medical condition: Seasonal influenza
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10022000 Influenza PT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: DE (Completed) FI (Completed)
    Trial results: View results
    EudraCT Number: 2021-003170-31 Sponsor Protocol Number: QHD00027 Start Date*: 2021-08-16
    Sponsor Name:Cardiovascular Non-Invasive Imaging Research Laboratory, Department of Cardiology, Herlev and Gentofte Hospital
    Full Title: Feasibility of Randomizing Danish Citizens Aged 65-79 Years to High-Dose Quadrivalent Influenza Vaccine vs. Standard-Dose Quadrivalent Influenza Vaccine in a Pragmatic Registry-Based Setting
    Medical condition: Prevention of influenza infection in adults aged 65-79 years
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10022000 Influenza PT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2009-014719-11 Sponsor Protocol Number: 2009/08 H1N1 Start Date*: 2009-09-18
    Sponsor Name:University of Oxford
    Full Title: Open Label, Randomized, Parallel-Group, Multi-Center Study to Evaluate the Safety, Tolerability and Immunogenicity of Baxter H1N1 vaccine and GlaxoSmithKline H1N1 vaccine in children 6 months to 12...
    Medical condition: Prophylaxis of influenza in an officially declared pandemic situation.
    Disease: Version SOC Term Classification Code Term Level
    12.0 10059429 Influenza immunisation LLT
    12.0 10059637 Influenza antibody test LLT
    12.0 10059642 Influenza antibody test positive LLT
    12.0 10059643 Influenza antibody test negative LLT
    12.0 10060063 Influenza serology LLT
    12.0 10060078 Influenza serology positive LLT
    12.0 10060079 Influenza serology negative LLT
    12.0 10022000 Influenza LLT
    12.0 10022002 Influenza A virus infection LLT
    12.0 10022001 Influenza (epidemic) LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2008-001079-31 Sponsor Protocol Number: V71P7S Start Date*: 2008-04-22
    Sponsor Name:NOVARTIS VACCINES AND DIAGNOSTICS S.R.L.
    Full Title: A Phase II, Open Label, Uncontrolled, Multi Center Study to Evaluate Safety and Immunogenicity of AGRIPPAL S1 Surface Antigen, Inactivated, Influenza Vaccine, Formulation 2008-2009, when Administer...
    Medical condition: Prophylaxis against flu virus 2008-2009.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10022005 HLT
    9.1 10022000 PT
    9.1 10022000 PT
    9.1 10022000 PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2019-004721-24 Sponsor Protocol Number: QHD00014 Start Date*: 2020-09-07
    Sponsor Name:Sanofi Pasteur Inc.
    Full Title: Efficacy, Immunogenicity, and Safety of High-Dose Quadrivalent Influenza Vaccine Compared with Standard-Dose Quadrivalent Influenza Vaccine in Children 6 Months through 35 Months of Age
    Medical condition: Prevention of influenza infection in children 6 months through 35 months of age
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10022000 Influenza PT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: (No results available)
    EudraCT Number: 2007-002894-30 Sponsor Protocol Number: 810703 Start Date*: 2007-09-27
    Sponsor Name:Baxter AG
    Full Title: AN OPEN-LABEL PHASE II STUDY TO ASSESS THE IMMUNOGENICITY AND SAFETY OF A BOOSTER VACCINATION WITH A HETEROLOGOUS VERO CELL-DERIVED WHOLE VIRUS H5N1 INFLUENZA VACCINE IN A HEALTHY YOUNG ADULT POPUL...
    Medical condition: Prophylaxis of H5N1 influenza infection in an officially declared pandemic situation. Pandemic influenza vaccine should be used in accordance with official guidance
    Disease: Version SOC Term Classification Code Term Level
    9.1 10022000 Influenza LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2016-004904-74 Sponsor Protocol Number: INFQ3003 Start Date*: 2017-09-07
    Sponsor Name:Abbott Biologicals B.V.
    Full Title: A Phase III, Observer-Blind, Randomized, Non-influenza Vaccine Comparator-Controlled, Parallel-Group, Multi-Country Study in Children Aged 6-35 Months to Assess the Safety and Efficacy of Abbott’s ...
    Medical condition: Prophylaxis of Influenza
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004862 10022005 Influenza viral infections HLT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: SK (Completed) DK (Completed) EE (Ongoing) CZ (Completed) LT (Completed) BG (Completed) IT (Completed) SI (Completed) ES (Completed) FR (Not Authorised) HR (Completed) HU (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2011-003314-16 Sponsor Protocol Number: FLUVALAB-H-15 Start Date*: 2011-08-30
    Sponsor Name:Omninvest Ltd.
    Full Title: A Randomized, Active Controlled, Double-blind, Multi-Centre Study to Evaluate Safety and Immunogenicity of One Dose of FLUVAL AB-like (Trivalent, Whole Virus, Aluminium Phosphate Gel Adjuvanted) In...
    Medical condition: Immunization of healthy people against influenza virus infection
    Disease: Version SOC Term Classification Code Term Level
    14.0 10042613 - Surgical and medical procedures 10059430 Influenza immunization LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed)
    Trial results: View results
    EudraCT Number: 2006-006307-37 Sponsor Protocol Number: 810601 Start Date*: 2007-05-15
    Sponsor Name:Baxter Innovations GmbH
    Full Title: AN OPEN LABEL PHASE III STUDY OF A VERO CELL-DERIVED WHOLE VIRUS H5N1 INFLUENZA VACCINE TO ASSESS THE IMMUNOGENICITY AND SAFETY AND TO INVESTIGATE THE NEED FOR AND TIMING OF A BOOSTER VACCINATION
    Medical condition: H5N1 Influenza vaccination in healthy subjects
    Disease: Version SOC Term Classification Code Term Level
    9.1 10022000 Influenza LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2009-017781-23 Sponsor Protocol Number: 720903 Start Date*: 2010-01-18
    Sponsor Name:Baxter Innovations GmbH
    Full Title: An Open Label Phase 3 Study to Assess the Safety and Immunogenicity of a Vero Cell-Derived Trivalent Seasonal Influenza Vaccine, Strain Composition 2009/2010, in an Adult Population
    Medical condition: To verify the safety and immunogenicity of a trivalent seasonal influenza vaccine with strain composition according to WHO/EU recommendation for the 2009/2010 season, manufactured according to the ...
    Disease: Version SOC Term Classification Code Term Level
    12.1 10022000 Influenza LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2011-005101-79 Sponsor Protocol Number: GQM04 Start Date*: 2012-10-05
    Sponsor Name:Sanofi Pasteur
    Full Title: Safety and Immunogenicity of a Quadrivalent Influenza Vaccine Administered via the Intramuscular Route in Child/Adolescent and Adult Subjects
    Medical condition: Prophylaxis of influenza in subjects from 9-17 years of age (and adults aged 18 to 60 years).
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10022001 Influenza (epidemic) LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2017-001044-35 Sponsor Protocol Number: GQM00016 Start Date*: 2019-02-08
    Sponsor Name:Sanofi Pasteur SA
    Full Title: Immunogenicity and Safety of a Multi-Dose Quadrivalent Influenza Vaccine in Children Aged 6 months to 17 Years
    Medical condition: Prophylaxis of influenza (Northern Hemisphere 2017-2018 season) in children aged 6 months to 17 years
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 29 19:06:15 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA